About Dizal Pharmaceutical Company

The company adheres to the innovative research and development concept at the source, with the goal of launching the world's first drugs (first-in-class) and treatments with breakthrough potential, with the aim of filling the world's unmet clinical needs. Based on industry-leading translational science and new drug molecular design and screening technology platforms, the company has established seven globally competitive product pipelines. Of these, two leading products in critical global clinical trials have all been approved for listing in China. The company is an innovative biomedical enterprise focusing on the research, development and commercialization of innovative therapies in the field of malignant tumors and immune diseases. The company's main products are sulvortinib tablets, golisitinib capsules, DZD8586, and DZD6008. The company was recognized by the Wuxi Municipal Bureau of Industry and Information Technology as “2022 Wuxi Specialized, Special and New Small and Medium Enterprises”; selected as “2022 China Pharmaceutical Emerging Innovation Force” published by China Pharmaceutical Industry Information Center; won the “2022 Changchun Award Innovative Pharmaceutical Enterprise of the Year” by Interface News; won the “2022 China Listed Company Reputation List - Biomedical's Most Growing Listed Company” hosted by the Shanghai Biomedical Technology Development Center and relevant organizations; selected as the “2022 Top 20 Most Influential Small Molecule Innovative Drug Companies” by the Shanghai Biomedical Technology Development Center and relevant organizations; in HR Media It was awarded honorary titles such as the “2022 Greater China Outstanding Employer Award” in the Greater China Human Resources Management Excellence Awards organized by the company HRoot.